Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05996432 · ClinicalTrials.gov registry record · Early Phase 1
Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy
A Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases, sponsored by Vanderbilt-Ingram Cancer Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05996432 is a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases that is actively recruiting participants, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 48 participants, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05996432, a Early Phase 1 study of Head and Neck Squamous Cell Carcinoma and Brain Metastases, is actively recruiting participants, sponsored by Vanderbilt-Ingram Cancer Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
Conditions Studied
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG 18F-fluoromisonidazole
Study Locations (1)
Tennessee
- Vanderbilt University/Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-05-17 |
| Est. Completion | 2029-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05996432
The ClinicalTrials.gov registry entry for NCT05996432 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (59% lower). The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT05996432 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05996432 about?
NCT05996432 is a clinical study titled "Image-Based, In-Vivo Assessment of Tumor Hypoxia to Guide Hypoxia-Driven Adaptive Radiation Therapy". This study will apply novel MRI approaches with established sensitivity to tissue oxygen consumption and perfusion to predict hypoxia-associated radiation resistance, manifested as tumor recurrence and progression post-treatment.
What is the current status of trial NCT05996432?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 48 participants. The study started on 2023-05-17. Estimated completion is 2029-05-31.
What conditions does trial NCT05996432 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma, Brain Metastases.
What interventions are being tested in trial NCT05996432?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), 18F-fluoromisonidazole (DRUG).
Who is sponsoring clinical trial NCT05996432?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05996432 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RECRUITING · Early Phase 1
-
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
RECRUITING · Early Phase 1
-
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
RECRUITING · Early Phase 1
-
Comparison of 89Zr Panitumumab and (18)F-Fluorodeoxyglucose to Identify Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
-
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
RECRUITING · Early Phase 1
-
PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
COMPLETED · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.